From owner-FreeBSD-users-jp@jp.FreeBSD.org Wed Dec  1 14:03:46 2004
Received: (from daemon@localhost)
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) id iB153kb58273;
	Wed, 1 Dec 2004 14:03:46 +0900 (JST)
	(envelope-from owner-FreeBSD-users-jp@jp.FreeBSD.org)
Received: from 222.98.114.227 (modemcable179.42-201-24.mc.videotron.ca [24.201.42.179])
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) with SMTP/inet id iB153i858268
	for <freebsd-users-jp@jp.freebsd.org>; Wed, 1 Dec 2004 14:03:45 +0900 (JST)
	(envelope-from xebeinfo@urgentalert.biz)
Message-Id: <200412010503.iB153i858268@castle.jp.FreeBSD.org>
Received: from mail.bellsouth.com (mail.bellsouth.com [139.76.165.130]) by mail.truetemper.com with smtp; Nov, 30 2004 10:41:24 PM +0300
From: MedCapCorp <xebeinfo@urgentalert.biz>
To: freebsd-users-jp@jp.FreeBSD.org
Mime-Version: 1.0
Content-Type: text/plain; charset="iso-8859-1"
X-Mailer: Microsoft Outlook Express 6.00.2462.0000
X-Priority: 1
Reply-To: FreeBSD-users-jp@jp.FreeBSD.org
Precedence: list
Date: Wed, 1 Dec 2004 00:03:45 -0500
X-Sequence: FreeBSD-users-jp 81976
Subject: [FreeBSD-users-jp 81976] update
Sender: owner-FreeBSD-users-jp@jp.FreeBSD.org
X-Originator: xebeinfo@urgentalert.biz
X-Distribute: distribute version 2.1 (Alpha) patchlevel 24e+041128

MedCap Corp Acquires Exclusive Rights to Rapid Test That Detects Sexually Transmitted Diseases

November 30, 2004

Toronto, Ontario

MedCap Corp (US NASD-OTC:MPCPF) is pleased to announce that it has acquired the exclusive right to 
market and distribute a rapid test kit for the detection of Syphilis. Syphilis is a sexually transmitted disease 
(STD) that is becoming more and more prevalent in many countries in the world. With early detection, 
Syphilis is easily cured through a single dose of penicillin taken as an intra muscular injection. World 
Health Organization (WHO) estimates that there are 340 million new cases of syphilis and other STD's 
each year. The largest number of new infections has occurred in South and Southeast Asia, followed by 
sub- Saharan Africa, Latin America and the Caribbean.

Individuals with Syphilis have a 3 to 5 time increase in the risk of transmitting and acquiring an HIV 
infection when Syphilis is present.

The Company feels that there is a virtually untouched market for a rapid diagnostic test kit related to the 
detection of Syphilis that is easy to use, a reasonable price and very accurate (greater than 99%). The 
acquisition of the exclusive rights to this Syphilis test kit will result in substantial cash flow for the 
Company.

MedCap Corp trades in the United States - NASD-OTC:MPCPF
http://biz.yahoo.com/prnews/041130/nytu059_1.html

For a detailed company bio and product information; 
http://stockwatchers.net-index.ph/click.php?id=onnecai

To unsubscribe from further news alerts;
http://stockwatchers.net-index.ph/click.php?id=onnecax

This release may contain forward-looking statements that involve uncertainties and risks. Actual results 
may differ materially from any results predicted. MedCap undertakes no obligation to release publicly any 
revisions to any forward-looking statements to reflect events of circumstances after the date hereof


gfaugdncrtuudvgvjxsbjanfagciudyrw
